Patent US2232261A successfully refreshed from Google Patents.
Patent US4278592A successfully refreshed from Google Patents.
US4278592A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process and apparatus for the production of sterile filtered blood clotting factors
Assignee: Individual
•
Filing: 1979-03-30
•
Granted: 1981-07-14
•
Expires: 1999-03-30
Abstract
Abstract A process and apparatus for the manufacture of sterile filtered blood clotting factore from fibrinogen with an enrichment of Factor I is provided. The process includes the step of extracting blood from at least one donor, manufacturing fibrinogen from the blood extracted in a known manner, dissolving the fibrinogen in a buffer, and effecting a sterile filtration of the buffer-dissolved fibrinogen by means of a static filtration device at a pressure of less than 0.5 atmospheres.
Inventors
- 👤 Arnold Seufert
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 07:53
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/745; C07K14/755; A; A61; A61K; A61K35/00; A61K35/12; A61K35/14; A61L; A61L2/00; A61L2/02; A61L2/022; C07K14/75; A61K38/00; A61L2103/00; A61L2103/05; A61L2103/09; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/829; Y10S530/83
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
135 words
A process for the manufacture of sterile filtered blood clotting products from fibrinogen with an enrichment of Factor 1, comprising the steps of: extracting blood from at least one donor; physically separating the blood to obtain substantially purified plasma, free of cellular componets, said separating step being carried out in a sequence of at least two centrifuging steps, to obtain plasma with an increasing degree of purity; deep freezing the purified plasma at a temperature below about minus 22° C.; thawing the plasma to produce a cyro-precipitate; drawing off the plasma present above the cyro-precipitate and manufacturing fibrinogen from said plasma in a known manner; dissolving the fibrinogen in a buffer; and effecting a sterile filtration of the buffer-dissolved fibrinogen by means of a static filtration device at a pressure of less tha 0.5 atm.
Claim 2
Dependent Claim
135 words
A process for the manufacture of sterile filtered blood clotting products from fibrinogen with an enrichment of Factor 1, comprising the steps of: extracting blood from at least one donor; physically separating the blood to obtain substantially purified plasma, free of cellular componets, said separating step being carried out in a sequence of at least two centrifuging steps, to obtain plasma with an increasing degree of purity; deep freezing the purified plasma at a temperature below about minus 22° C.; thawing the plasma to produce a cyro-precipitate; drawing off the plasma present above the cyro-precipitate and manufacturing fibrinogen from said plasma in a known manner; dissolving the fibrinogen in a buffer; and effecting a sterile filtration of the buffer-dissolved fibrinogen by means of a static filtration device at a pressure of less tha 0.5 atm.
Claim 3
Dependent Claim
15 words
The process according to claim 1, wherein said blood is extracted from a single donor.
Claim 4
Dependent Claim
22 words
The process according to claim 1, wherein said sterile filtration step is carried out in a sterile chamber to prevent secondary contamination.
Claim 5
Dependent Claim
30 words
The process according to claim 1, additionally including the step of carrying out a bubble-point test after said sterile filtration step, to ensure that the process has proceeded without error.
Claim 6
Dependent Claim
21 words
The process according to claim 1, wherein said process steps are repeated following purification and autoclaving of the filtration apparatus employed.
Claim 7
Dependent Claim
58 words
The process according to claim 1, wherein said manufacturing step comprises the following substeps: cooling the plasma drawn off down to 0° C. and mixing said cooled plasma with alcohol so as to achieve a solution containing about 8% alcohol and to thereby obtain a fibrinogen precipitate; and physicially separating said fibrinogen precipitate from said solution by centrifuging.
References Cited (Backward Citations)
US4141887A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-07-13 | 1985-01-12 | 1985-07-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-07-13 | 1989-01-12 | 1989-07-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-07-13 | 1993-01-12 | 1993-07-14 | $7700.00 | Window Closed / Lapsed |